OSU-DY-7

N/A

Report date: 2022/07/01 15:29:28
NME

Base Information

Drug NameOSU-DY-7
Drug Alias NameOSU-DY-7OSU-DY7
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP38 mitogen-activated protein kinase inhibitors
TargetsP38 mitogen-activated protein kinase
Therapy Area/IndicationsLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesThe Ohio State University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe Ohio State University
Active IndicationsN/A
Inactive IndicationsLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A